(Q38345599)

2 September 2017

1 reference

title

Management of diffuse large B-cell lymphoma (DLBCL). (English)

1 reference

diffuse large B-cell lymphoma

2 September 2017

1 reference

1 reference

3

Michael Pfreundschuh

0 references

author name string

Boris Kubuschok

series ordinal

1

1 reference

2 September 2017

Gerhard Held

series ordinal

2

1 reference

2 September 2017

publication date

1 January 2015

1 reference

Cancer Treatment and Research

2 September 2017

published in

1 reference

2 September 2017

volume

165

1 reference

2 September 2017

page(s)

271-288

1 reference

Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Diffuse large cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Molecular pathogenesis of diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Molecular diagnosis of Burkitt's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Double-hit B-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Revised response criteria for malignant lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Crosstalk between RANKL and Fas signaling in dendritic cells controls immune tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Clinical assessment of elderly people with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Perioperative or postoperative therapy for resectable gastric cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Suboptimal dosing of rituximab in male and female patients with DLBCL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Idelalisib--a PI3Kδ inhibitor for B-cell cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_11

10.1007/978-3-319-13150-4_11

31 March 2020

Identifiers

DOI

1 reference

2 September 2017

1 reference